Peroxisome Proliferator-Activated Receptor Modulation in Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a progressive microvascular complication characterised by albuminuria, declining glomerular filtration rate and eventual renal fibrosis. Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors with three isoforms (α, β/δ and γ) that regulate gene networks controlling lipid and glucose metabolism, inflammatory signalling and extracellular matrix turnover within the kidney. Activation of PPARγ improves insulin sensitivity and directly protects glomerular podocytes by stabilising cytoskeletal architecture and attenuating transforming growth factor-β-driven fibrosis. PPARα promotes fatty acid β-oxidation in proximal tubules, reducing lipotoxicity and inflammatory cytokine release. Emerging selective PPAR modulators aim to maintain therapeutic efficacy while limiting fluid retention and cardiovascular side effects seen with first-generation thiazolidinediones. Advances in understanding the coactivators, ubiquitin ligases and post-translational modifications that fine-tune PPAR activity under hyperglycaemic stress have revealed novel intervention points to sustain autophagy and suppress profibrotic gene expression. Collectively, strategic modulation of PPAR signalling presents a globally significant approach to slow glomerulosclerosis, preserve renal function and reduce the burden of end-stage kidney disease in patients with type 1 and type 2 diabetes.

Research from Nature Portfolio

Recent studies have demonstrated that adjunctive treatment with a thiazolidinedione can potentiate glucocorticoid efficacy in proteinuric kidney injury. In experimental models of podocyte damage, combining a PPARγ agonist with low-dose glucocorticoids restored proteinuria reduction to levels achieved by high-dose steroids alone. This synergistic effect was accompanied by enhanced glomerular expression of podocyte structural proteins and suppressed inflammatory mediators, suggesting a strategy to minimise steroid exposure while preserving glomerular integrity in diabetic nephropathy.

Peroxisome Proliferator-Activated Receptor Modulation in Diabetic Kidney Disease publication trend

The graph below shows the total number of articles in peroxisome proliferator-activated receptor modulation in diabetic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Peroxisome proliferator-activated receptors (PPARs): A family of ligand-activated nuclear receptors that regulate genes involved in lipid and glucose metabolism, inflammation and fibrosis.

Podocyte: A specialised epithelial cell in the kidney glomerulus essential for maintaining the filtration barrier and preventing proteinuria.

Autophagy: A cellular process for degrading and recycling damaged organelles and proteins, preserving cell health under stress conditions such as hyperglycaemia.

Fibrosis: The excessive deposition of extracellular matrix components leading to organ scarring and loss of function in chronic kidney disease.

References

1. Deficiency of Nuclear Receptor Coactivator 3 Aggravates Diabetic Kidney Disease by Impairing Podocyte Autophagy. Advanced Science (2024).
2. Impact of Ring Finger Protein 20 and Its Downstream Regulation on Renal Tubular Injury in a Unilateral Nephrectomy Mouse Model Fed a High-Fat Diet. Nutrients (2023).
3. Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. Scientific Reports (2016).